{"schema_version":"1","generated_at":"2026-11-04T09:01:13.186Z","data_as_of":null,"url":"https://www.findmykol.com/kol/prajwal-boddu","json_url":"https://www.findmykol.com/kol/prajwal-boddu/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"prajwal-boddu","name":"Prajwal Boddu","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Yale Cancer Center","institution_url":"https://www.findmykol.com/institution/yale-school-of-medicine","city":"New Haven","state":"CT","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1205178621","orcid":"0000-0001-9408-5882","openalex":"A5102765905"},"summary":"Prajwal Boddu is an Oncology physician affiliated with Yale Cancer Center. OpenAlex indexes 125 publications with 3,650 citations (h-index 30).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":125,"cited_by_count":3650,"h_index":30,"latest_activity_year":2026,"source":"works"},"prescribing":{"data_year":2019,"areas_total":2,"areas_shown":2,"areas":[{"area":"Metabolism & gastrointestinal","share_pct":67.6,"classes_total":2,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":35.3,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":null},{"class":"Antidiarrheal microorganisms","setting":"prescribed","share_pct":32.4,"drugs":[{"name":"Zenpep","share_pct":100}],"max_beneficiaries":null}]},{"area":"Cancer & immunology","share_pct":32.4,"classes_total":1,"classes":[{"class":"Cytochrome P450 17A1 Inhibitor","setting":"prescribed","share_pct":32.4,"drugs":[{"name":"Zytiga","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"funding":{"award_count":1,"fiscal_years":{"first":2024,"last":2026},"rows_total":3,"shown":3,"withheld":0,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"K08DK140636","title":"Therapeutic Targeting of Transcription-Driven Epigenetic Defects in SF3B1 Mutant Myelodysplastic syndromes (MDS)","fiscal_year":2026,"amount_usd":"168048","organization":"YALE UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/K08DK140636"},{"project":"K08DK140636","title":"Therapeutic Targeting of Transcription-Driven Epigenetic Defects in SF3B1 Mutant Myelodysplastic syndromes (MDS)","fiscal_year":2025,"amount_usd":"168048","organization":"YALE UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/K08DK140636"},{"project":"K08DK140636","title":"Therapeutic Targeting of Transcription-Driven Epigenetic Defects in SF3B1 Mutant Myelodysplastic syndromes (MDS)","fiscal_year":2024,"amount_usd":"169548","organization":"YALE UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/K08DK140636"}],"source":"grants"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape","year":2024,"journal":"Molecular Cell","source_url":"https://doi.org/10.1016/j.molcel.2024.02.032","status":"verified"},{"title":"The FANCI/FANCD2 complex links DNA damage response to R-loop regulation through SRSF1-mediated mRNA export","year":2024,"journal":"Cell Reports","source_url":"https://doi.org/10.1016/j.celrep.2023.113610","status":"verified"},{"title":"Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications","year":2021,"journal":"Frontiers in Immunology","source_url":"https://doi.org/10.3389/fimmu.2020.590494","status":"verified"},{"title":"Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts","year":2020,"journal":"The Lancet Haematology","source_url":"https://doi.org/10.1016/s2352-3026(20)30205-2","status":"verified"},{"title":"Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy","year":2020,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2020-139752","status":"verified"}],"source":"works"},"contact":{"address_1":"333 CEDAR ST","city":"New Haven","state":"CT","zip":"065103206","phone":"832-396-4414","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1205178621","source":"identity"},"similar":[{"name":"Ian Krop","slug":"ian-krop","institution":"Yale Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/ian-krop","json_url":"https://www.findmykol.com/kol/ian-krop/profile.json"},{"name":"Harriet Kluger","slug":"harriet-kluger","institution":"Yale Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/harriet-kluger","json_url":"https://www.findmykol.com/kol/harriet-kluger/profile.json"},{"name":"Stephanie Halene","slug":"stephanie-halene","institution":"Yale Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/stephanie-halene","json_url":"https://www.findmykol.com/kol/stephanie-halene/profile.json"},{"name":"John Kunstman","slug":"john-kunstman","institution":"Yale Cancer Center","specialty":"Surgical Oncology","url":"https://www.findmykol.com/kol/john-kunstman","json_url":"https://www.findmykol.com/kol/john-kunstman/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2023-06-20","provider_certified":"2023-06-20","collected_at":"2026-11-03T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2019},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}